{
    "N/R/U": null,
    "Applicant": "Regeneron Pharmaceuticals, Inc.",
    "BLA Number": "761055",
    "Proprietary Name": "Dupixent",
    "Proper Name": "dupilumab",
    "BLA Type": "351(a)",
    "Strength": "300MG/2ML",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "June 18, 2020",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "17",
    "Submission Type": "Supplement",
    "License Number": "1760",
    "Product Number": "004",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "January 25, 2031"
}